Lessons from a bad gene therapy trial for Duchenne muscular dystrophy

.Attribute Medication, Posted online: 09 October 2024 doi:10.1038/ s41591-024-03316-9Delandistrogene moxeparvovec obtained FDA permission after a negative test, which highlights the numerous difficulties and also problems of medication progression in this environment.